Changes in the prescription of cardiovascular prevention drugs in France between 1995 and 2003: factors influencing the gap between evidence base medicine and clinical practice;Evolution des prescriptions des classes thérapeutiques cardiovasculaires majeures en prévention secondaire en France de 1995 a 2003: les raisons décelables d'un ecart entre la médecine fondée sur les preuves et la pratique.

Annales de cardiologie et d'angéiologie

Volumn 54 Suppl 1, Issue , 2005, Pages

  Philippe, François ^a   Cambou, Jean Pierre ^a   Danchin, Nicolas ^a   Thomas, Daniel ^a  

^a INSTITUT MUTUALISTE MONTSOURIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASE; CLINICAL MEDICINE; EVIDENCE BASED MEDICINE; FRANCE; HUMAN; PRESCRIPTION; REVIEW; STATISTICS;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; CLINICAL MEDICINE; EVIDENCE-BASED MEDICINE; FRANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; PRESCRIPTIONS, DRUG;

EID: 33645576303     PISSN: 00033928     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)